JP2011079858A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011079858A5 JP2011079858A5 JP2010274944A JP2010274944A JP2011079858A5 JP 2011079858 A5 JP2011079858 A5 JP 2011079858A5 JP 2010274944 A JP2010274944 A JP 2010274944A JP 2010274944 A JP2010274944 A JP 2010274944A JP 2011079858 A5 JP2011079858 A5 JP 2011079858A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer therapeutic
- therapeutic agent
- cancer
- drug
- human lactoferrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 18
- 201000011510 cancer Diseases 0.000 claims 15
- 229940078795 Lactoferrin Drugs 0.000 claims 7
- 102000010445 Lactoferrin Human genes 0.000 claims 7
- 108010063045 Lactoferrin Proteins 0.000 claims 7
- 229940079593 drugs Drugs 0.000 claims 7
- 235000021242 lactoferrin Nutrition 0.000 claims 7
- 239000004480 active ingredient Substances 0.000 claims 4
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- 230000001225 therapeutic Effects 0.000 claims 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229960003668 docetaxel Drugs 0.000 claims 3
- 229960004316 cisplatin Drugs 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Claims (10)
- 扁平上皮細胞癌、乳癌、卵巣癌、および胃癌からなる群より選択される定着固形癌を治療する為の癌治療薬であって、ヒトラクトフェリンを該癌治療薬の有効成分として含有する経口医薬組成物を含む癌治療薬。
- 前記ヒトラクトフェリンが、前記経口医薬組成物において、薬学的に許容される担体中に分散されている、請求項１記載の癌治療薬。
- 該ヒトラクトフェリンが組換えヒトラクトフェリンである、請求項１または２記載の癌治療薬。
- 前記ヒトラクトフェリンを該癌治療薬の有効成分として含有する経口医薬組成物に、さらに化学療法用薬剤を組合せてなる、請求項１から３までのいずれかに記載の癌治療薬。
- 前記化学療法用薬剤が、白金系の薬剤を含む、請求項４記載の癌治療薬。
- 前記白金系の薬剤がシスプラチンである、請求項５記載の癌治療薬。
- 前記ヒトラクトフェリンを該癌治療薬の有効成分として含有する経口医薬組成物の投与が、シスプラチン投与前あるいはシスプラチン投与と同時に行われる、請求項６記載の癌治療薬。
- 前記化学療法用薬剤が、タキサン系の薬剤を含む、４から７までのいずれかに記載の治療薬。
- 前記タキサン系の薬剤が、ドセタキセルである、請求項８記載の癌治療薬。
- 前記ヒトラクトフェリンを該癌治療薬の有効成分として含有する経口医薬組成物の投与が、ドセタキセル投与前あるいはドセタキセル投与と同時に行われる、請求項９記載の癌治療薬。
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37947402P | 2002-05-10 | 2002-05-10 | |
| US37944102P | 2002-05-10 | 2002-05-10 | |
| US37944202P | 2002-05-10 | 2002-05-10 | |
| US60/379,441 | 2002-05-10 | ||
| US60/379,474 | 2002-05-10 | ||
| US60/379,442 | 2002-05-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004506847A Division JP4685443B2 (ja) | 2002-05-10 | 2003-05-09 | 悪性新生物および他の過剰増殖性疾患の治療におけるラクトフェリン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011079858A JP2011079858A (ja) | 2011-04-21 |
| JP2011079858A5 true JP2011079858A5 (ja) | 2011-08-04 |
| JP5156084B2 JP5156084B2 (ja) | 2013-03-06 |
Family
ID=29424524
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004506847A Expired - Fee Related JP4685443B2 (ja) | 2002-05-10 | 2003-05-09 | 悪性新生物および他の過剰増殖性疾患の治療におけるラクトフェリン |
| JP2010274944A Expired - Fee Related JP5156084B2 (ja) | 2002-05-10 | 2010-12-09 | 定着固形癌の治療におけるラクトフェリン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004506847A Expired - Fee Related JP4685443B2 (ja) | 2002-05-10 | 2003-05-09 | 悪性新生物および他の過剰増殖性疾患の治療におけるラクトフェリン |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US20040082504A1 (ja) |
| EP (2) | EP2286827A1 (ja) |
| JP (2) | JP4685443B2 (ja) |
| CN (2) | CN100467059C (ja) |
| AT (1) | ATE519499T1 (ja) |
| AU (2) | AU2003239393A1 (ja) |
| CA (1) | CA2484656A1 (ja) |
| CY (1) | CY1111999T1 (ja) |
| DK (1) | DK1507554T3 (ja) |
| HK (2) | HK1080722A1 (ja) |
| PT (1) | PT1507554E (ja) |
| WO (2) | WO2003094952A1 (ja) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399570B1 (en) * | 1999-02-05 | 2002-06-04 | Agennix, Inc. | Antimicrobial/endotoxin neutralizing polypeptide |
| US20040082504A1 (en) | 2002-05-10 | 2004-04-29 | Atul Varadhachary | Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| AU2003233583A1 (en) * | 2002-05-24 | 2003-12-12 | Agennix Incorporated | Oral lactoferrin in the treatment of respiratory disorders |
| ES2358645T3 (es) * | 2002-09-16 | 2011-05-12 | Agennix Incorporated | Composiciones de lactoferrina y métodos de tratamiento de la úlcera diabética. |
| EP1581243A4 (en) * | 2002-12-06 | 2008-01-02 | Agennix Inc | ORAL LACTOFERRINE FOR THE TREATMENT OF SEPSIES |
| US7592306B2 (en) * | 2002-12-10 | 2009-09-22 | Agennix, Inc. | Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease |
| AU2003293500A1 (en) * | 2002-12-12 | 2004-07-09 | Agennix Incorporated | Lactoferrin in the reduction of pain |
| US8105615B2 (en) * | 2003-06-06 | 2012-01-31 | Agennix Incorporated | Lactoferrin as an adjuvant in cancer vaccines |
| WO2005018542A2 (en) * | 2003-07-10 | 2005-03-03 | Agennix Incorporated | Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects |
| GB0413954D0 (en) * | 2004-06-22 | 2004-07-28 | Altunkaya Ali | Compositions for topical treatment |
| US7183381B2 (en) * | 2004-10-26 | 2007-02-27 | Agennix, Inc. | Composition of lactoferrin related peptides and uses thereof |
| CA2587727A1 (en) * | 2004-11-19 | 2006-05-26 | Jagat Rakesh Kanwar | Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer |
| WO2007022537A2 (en) * | 2005-08-19 | 2007-02-22 | Agennix Incorporated | Use of lactoferrin as a chemokine and a chemotactic modulator |
| US20100215631A1 (en) * | 2006-06-14 | 2010-08-26 | Anita Hartog | Anti-inflammatory composition comprising glycine and lactoferrin and the use thereof |
| CN102215836B (zh) * | 2008-09-19 | 2015-07-08 | 雀巢产品技术援助有限公司 | 预防或减轻在抗癌治疗期间的骨髓瘫痪或中性白细胞减少症的营养支持 |
| EP2391225B1 (en) * | 2009-01-28 | 2020-05-06 | Jean-Paul Perraudin | Method for production of lactoferrin |
| US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
| US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
| JP2015067560A (ja) * | 2013-09-27 | 2015-04-13 | 国立大学法人広島大学 | ラクトフェリンを含有する癌転移抑制剤 |
| US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
| WO2015089316A1 (en) * | 2013-12-12 | 2015-06-18 | Cornell University | Methods for preventing and treating oral cancers |
| US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
| CN106174462A (zh) * | 2016-04-17 | 2016-12-07 | 马鞍山市志诚科技有限公司 | 一种防治血管瘤的营养配方纳米颗粒及制备加工方法 |
| WO2018079701A1 (ja) * | 2016-10-28 | 2018-05-03 | 株式会社Ｎｒｌファーマ | ラクトフェリン活性を有するタンパク質を含む、抗ガン治療補助剤 |
| CN111544579A (zh) * | 2020-03-13 | 2020-08-18 | 中国农业科学院北京畜牧兽医研究所 | 一种抗癌症的药物组合物 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6351337A (ja) | 1986-08-22 | 1988-03-04 | Snow Brand Milk Prod Co Ltd | 抗腫瘍剤 |
| US4977137B1 (en) | 1987-06-03 | 1994-06-28 | Baylor College Medicine | Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract |
| IL94183A (en) | 1989-05-05 | 2003-09-17 | Baylor College Medicine | cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE |
| US5849881A (en) | 1989-05-05 | 1998-12-15 | Baylor College Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms |
| US5571691A (en) | 1989-05-05 | 1996-11-05 | Baylor College Of Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms |
| US6100054A (en) * | 1989-05-05 | 2000-08-08 | Baylor College Of Medicine | Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms |
| US5571697A (en) | 1989-05-05 | 1996-11-05 | Baylor College Of Medicine Texas Medical Center | Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus |
| US5766939A (en) * | 1989-05-05 | 1998-06-16 | Baylor College Of Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms |
| US5198419A (en) | 1989-12-08 | 1993-03-30 | Immuno Japan Inc. | Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria |
| ES2109362T3 (es) | 1991-06-21 | 1998-01-16 | Univ Cincinnati | Unas proteinas administrables oralmente y metodo para hacerlas. |
| JP3184923B2 (ja) | 1992-01-08 | 2001-07-09 | ビオ セレ ラボラトワール エス ア | 抗リウマチ剤 |
| ZA932568B (en) | 1992-04-24 | 1993-11-12 | Baylor College Midecine A Non | Production of recombinant human lactoferrin |
| CA2086874E (en) * | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
| US5679807A (en) | 1995-01-30 | 1997-10-21 | Hauser, Inc. | Preparation of taxol and docetaxel through primary amines |
| JPH08217693A (ja) | 1995-02-17 | 1996-08-27 | Yoshihisa Naito | 新規医薬組成物 |
| JP3888707B2 (ja) * | 1996-01-22 | 2007-03-07 | 森永乳業株式会社 | 血管新生病治療剤 |
| JP3496387B2 (ja) | 1996-01-23 | 2004-02-09 | 花王株式会社 | 毛髪化粧料 |
| US6111081A (en) | 1996-05-31 | 2000-08-29 | Baylor College Of Medicine | Lactoferrin variants and uses thereof |
| EP0920331A1 (en) | 1996-08-12 | 1999-06-09 | A+ Science Invest AB | Treatment and prevention of infections, inflammations and/or tumours with lactoferrin and/or lactoferricin |
| JP2002515893A (ja) | 1997-02-03 | 2002-05-28 | ファーミング インテレクチュアル プロパティ ビーブイ | ヒトラクトフェリンおよびその改変体の有用な特性 |
| EP0979099B1 (en) | 1997-04-10 | 2005-06-15 | Agennix, Inc. | Use of lactoferin in the treatment of allergen induced disorders |
| DE69914911T2 (de) | 1998-06-26 | 2004-12-09 | Naamloze Vennootschap Nutricia | Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen |
| GB9818938D0 (en) * | 1998-08-28 | 1998-10-21 | Alpharma As | Bioactive peptides |
| US6399570B1 (en) | 1999-02-05 | 2002-06-04 | Agennix, Inc. | Antimicrobial/endotoxin neutralizing polypeptide |
| JP2000229881A (ja) | 1999-02-10 | 2000-08-22 | Morinaga Milk Ind Co Ltd | 癌疾患の予後改善剤 |
| RU2165769C1 (ru) | 2000-07-13 | 2001-04-27 | Якубовская Раиса Ивановна | Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения |
| US20030096736A1 (en) * | 2001-05-09 | 2003-05-22 | Kruzel Marian L. | Lactoferrin for age related disorders in humans |
| US20040082504A1 (en) * | 2002-05-10 | 2004-04-29 | Atul Varadhachary | Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| AU2003233583A1 (en) | 2002-05-24 | 2003-12-12 | Agennix Incorporated | Oral lactoferrin in the treatment of respiratory disorders |
| ES2358645T3 (es) * | 2002-09-16 | 2011-05-12 | Agennix Incorporated | Composiciones de lactoferrina y métodos de tratamiento de la úlcera diabética. |
| US8105615B2 (en) * | 2003-06-06 | 2012-01-31 | Agennix Incorporated | Lactoferrin as an adjuvant in cancer vaccines |
| WO2005018542A2 (en) * | 2003-07-10 | 2005-03-03 | Agennix Incorporated | Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects |
| CA2587727A1 (en) | 2004-11-19 | 2006-05-26 | Jagat Rakesh Kanwar | Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer |
| JP2007233064A (ja) | 2006-03-01 | 2007-09-13 | Bitsign:Kk | 表示システム及び表示器 |
-
2003
- 2003-05-09 US US10/435,319 patent/US20040082504A1/en not_active Abandoned
- 2003-05-09 CN CNB038163853A patent/CN100467059C/zh not_active Expired - Fee Related
- 2003-05-09 WO PCT/US2003/014584 patent/WO2003094952A1/en not_active Application Discontinuation
- 2003-05-09 EP EP10010751A patent/EP2286827A1/en not_active Withdrawn
- 2003-05-09 AU AU2003239393A patent/AU2003239393A1/en not_active Abandoned
- 2003-05-09 DK DK03755357.5T patent/DK1507554T3/da active
- 2003-05-09 US US10/434,769 patent/US7901879B2/en not_active Expired - Fee Related
- 2003-05-09 JP JP2004506847A patent/JP4685443B2/ja not_active Expired - Fee Related
- 2003-05-09 PT PT03755357T patent/PT1507554E/pt unknown
- 2003-05-09 AT AT03755357T patent/ATE519499T1/de active
- 2003-05-09 CA CA002484656A patent/CA2484656A1/en not_active Abandoned
- 2003-05-09 WO PCT/US2003/014789 patent/WO2003099323A1/en active Application Filing
- 2003-05-09 CN CNB038163918A patent/CN100467060C/zh not_active Expired - Fee Related
- 2003-05-09 AU AU2003273182A patent/AU2003273182B8/en not_active Ceased
- 2003-05-09 EP EP03755357A patent/EP1507554B1/en not_active Expired - Lifetime
-
2006
- 2006-01-13 HK HK06100605.1A patent/HK1080722A1/xx not_active IP Right Cessation
- 2006-03-14 HK HK06103271.8A patent/HK1083203A1/xx not_active IP Right Cessation
-
2009
- 2009-09-17 US US12/561,429 patent/US20100137208A1/en not_active Abandoned
-
2010
- 2010-12-09 US US12/964,327 patent/US8242079B2/en not_active Expired - Fee Related
- 2010-12-09 JP JP2010274944A patent/JP5156084B2/ja not_active Expired - Fee Related
-
2011
- 2011-11-03 CY CY20111101064T patent/CY1111999T1/el unknown
-
2012
- 2012-07-11 US US13/546,208 patent/US20120276126A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011079858A5 (ja) | ||
| JP2013527232A5 (ja) | ||
| NZ708506A (en) | Methods of treating bladder cancer | |
| JP2017171685A5 (ja) | ||
| EA201401028A1 (ru) | Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения | |
| JP2013533232A5 (ja) | ||
| NZ707377A (en) | Combination therapy methods for treating proliferative diseases | |
| JP2012506448A5 (ja) | ||
| JP2009515901A5 (ja) | ||
| JP2012082215A5 (ja) | ||
| JP2015515475A5 (ja) | ||
| MX2010002409A (es) | Composiciones y metodos para la distribucion de farmacos escasamente solubles. | |
| NZ588913A (en) | Liver cancer drug | |
| JP2006524246A5 (ja) | ||
| JP2013542205A5 (ja) | ||
| JP2013518124A5 (ja) | ||
| JP2009539994A5 (ja) | ||
| JP2015507020A5 (ja) | ||
| JP2014506233A5 (ja) | ||
| JP2018522028A5 (ja) | ||
| PH12014502619A1 (en) | Novel dosage and formulation | |
| JP2019530706A5 (ja) | ||
| JP2012505830A5 (ja) | ||
| JP2015510945A5 (ja) | ||
| RU2010140888A (ru) | Улучшенные противораковые терапии |